Comprehensive biomarker testing using a validated multigene panel at diagnosis, rather than sequential single-gene testing, helps identify epidermal growth factor receptor (EGFR) mutations before treatment initiation, enabling clinicians to consider the full range of evidence-based first-line treatment options.1 Classical mutations and less common activating mutations can guide regimen choice, since guideline-preferred options differ somewhat by mutation subtype.1
Delays in testing or treatment initiation may result in patients starting off with a less-tailored regimen, or progress before molecular results return. This is increasingly important as first-line treatment options for EGFR-mutated mNSCLC now include oral EGFR tyrosine kinase inhibitors (TKI) monotherapy as well as combination regimens, each with distinct efficacy, toxicity profiles, administration logistics, and monitoring considerations. Comprehensive biomarker results before treatment initiation allow clinicians and patients to evaluate the full range of evidence-based first-line options.2
Comprehensive testing completion is not uniform across care settings, given documented barriers such as complex reimbursement processes, uncertainties around clinical utility, insurance policies that may be more restrictive than guideline recommendations, and inadequate infrastructure or staff training.3 Testing failure, though less common, can compound these gaps further, leaving clinicians without actionable results and forcing a choice between empiric treatment or repeat biopsy.4
As the number of first-line pathways expands, timely, complete testing becomes more consequential, not less. For referring and treating clinicians alike, reinforcing testing turnaround expectations and coordinating early with molecular pathology may help ensure patients begin appropriate therapy without avoidable delay.
Take our mNSCLC quiz to see how your knowledge compares to your peers.
